| SCN8A — Sodium Voltage-Gated Channel Alpha Subunit 8 | |
|---|---|
| Symbol | SCN8A |
| Full Name | Sodium Voltage-Gated Channel Alpha Subunit 8 |
| Chromosome | 12q13.13 |
| NCBI Gene | 6334 |
| Ensembl | ENSG00000175550 |
| OMIM | 600402 |
| UniProt | Q9UQD0 |
| Diseases | Epilepsy, Cognitive Impairment, Movement Disorders, Alzheimer's Disease |
| Expression | Brain, Cerebellum, Hippocampus, Cortex |
| Key Mutations | |
| N1768D, R1872H, R1617Q | |
Scn8A Gene Nav1.6 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SCN8A (Sodium Voltage-Gated Channel Alpha Subunit 8) is a gene located on chromosome 12q13.13 that encodes the Nav1.6 voltage-gated sodium channel, a critical ion channel protein expressed predominantly in the central nervous system[1]. The gene is catalogued as NCBI Gene ID 6334 and OMIM 600402.
Nav1.6 is one of the primary sodium channels responsible for action potential initiation and propagation in neurons. It is particularly abundant in the axon initial segment (AIS) and nodes of Ranvier, where it plays a essential role in neuronal excitability[2].
The SCN8A gene encodes the alpha subunit of the voltage-gated sodium channel Nav1.6. This protein forms the pore of the channel and contains the voltage sensor that detects changes in membrane potential.
The Nav1.6 channel consists of a large alpha subunit (∼260 kDa) that forms the functional ion channel, associated with auxiliary beta subunits that modulate channel trafficking and function[3]. The alpha subunit contains four homologous domains (I-IV), each with six transmembrane segments (S1-S6). The S4 segments serve as voltage sensors, while the S5-S6 segments form the pore.
SCN8A exhibits high expression in multiple brain regions:
Expression data is available from the Allen Human Brain Atlas.
Nav1.6 channels are critical for:
SCN8A mutations are linked to several neurological conditions:
De novo missense mutations in SCN8A are a well-established cause of early-onset epileptic encephalopathy[4]. These mutations typically result in gain-of-function, leading to increased neuronal excitability. Affected individuals present with infantile spasms, focal seizures, and refractory epilepsy.
SCN8A mutations are associated with intellectual disability, developmental delay, and autism spectrum disorders[5]. The severity correlates with mutation type and location.
Mutations can cause ataxia, dystonia, and tremor due to dysfunction in cerebellar and basal ganglia circuits[6].
Recent research suggests SCN8A may play a role in Alzheimer's disease pathogenesis. Sodium channel dysfunction contributes to amyloid-beta toxicity and tau-induced neuronal injury[7].
| Mutation | Effect | Associated Phenotype |
|---|---|---|
| N1768D | Gain-of-function | Severe early-onset epilepsy |
| R1872H | Gain-of-function | Epilepsy, developmental delay |
| R1617Q | Loss-of-function | Ataxia, movement disorder |
Several sodium channel blockers have been investigated for SCN8A-related disorders:
SCN8A interacts with several proteins:
The study of Scn8A Gene Nav1.6 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.